Protalix's core business model centers on commercializing recombinant proteins via its proprietary plant cell technology, with a heavy reliance on the Chiesi partnership for revenue growth. The differentiation mainly stems from its ProCellEx platform and strategic collaborations rather than unique …
Protalix BioTherapeutics (PLX) FY 2024: 31% Revenue Growth Driven by Chiesi Partnership and Pipeline Progress
Protalix BioTherapeutics achieved a significant 31% increase in revenues from selling goods in 2024, propelled by strong sales to its key partner Chiesi. The company advanced its clinical pipeline with promising Phase I data for PRX-115 and prepared for a Phase II trial, while maintaining a strengthened balance sheet after full debt repayment. These developments position Protalix to capitalize on growth opportunities in rare diseases and gout treatment.
Summary
- Commercial Momentum with Chiesi: Sustained revenue growth driven by increased sales and strategic collaboration on Elfabrio.
- Pipeline Advancement: Positive Phase I results for PRX-115 support initiation of Phase II clinical trial in 2025.
- Financial Strength: Full repayment of convertible notes and warrant exercises bolster balance sheet for future R&D investments.
Business Overview
Protalix BioTherapeutics is a biopharmaceutical company specializing in recombinant therapeutic proteins produced via its proprietary ProCellEx plant cell-based expression system. The company generates revenue primarily through sales of its approved product Elfabrio, commercialized globally in partnership with Chiesi, and through license and R&D service agreements with partners like Pfizer. Its business segments include commercial product sales, license and R&D services, and an advancing pipeline focused on rare diseases and gout treatment candidates.
Performance Analysis
In fiscal 2024, Protalix reported revenues from selling goods of $53.0 million, a 31% increase from $40.4 million in 2023. This growth was driven predominantly by an $11.8 million increase in sales to Chiesi, reflecting the partner’s intensified commercial focus and investment in Elfabrio’s medical and marketing programs. Additional modest contributions came from Brazil and Pfizer sales. However, revenues from license and R&D services plummeted 98% to $0.4 million, primarily due to the completion of regulatory milestones and clinical programs related to Elfabrio in 2023, including a $20 million milestone payment from Chiesi in that year.
Cost of goods sold rose moderately by 6% to $24.3 million, correlating with the higher sales volume to Chiesi. Research and development (R&D) expenses decreased 24% to approximately $13.0 million, reflecting the completion of the Fabry disease clinical program and regulatory processes. Selling, general and administrative (SG&A) expenses also declined by 19% to $12.2 million, driven by lower professional fees and salary expenses. The company reported a net income of $2.9 million for 2024, down from $8.3 million in 2023, influenced by the absence of large milestone revenues but supported by lower expenses and improved financial income following debt repayment.
- Revenue Growth Concentration: The 31% increase was almost entirely due to Chiesi sales, underscoring dependence on this strategic partner.
- Expense Management: Reduced R&D and SG&A spending indicate a shift from late-stage clinical development to early-stage pipeline focus.
- Net Income Dynamics: Earnings reflect the transition from milestone-driven revenues to steady product sales and controlled costs.
Overall, Protalix’s financial performance in 2024 demonstrates a successful transition from clinical milestone dependency to a more sustainable commercial revenue base, while maintaining disciplined expense control to support ongoing innovation.
Executive Commentary
"2024 was a record year in revenues from selling goods for Protalix, as we experienced increases in all three of our revenue streams, Chiesi, Pfizer and Brazil. We are pleased with the promising results from our first-in-human study of our gout candidate, PRX-115, in adult volunteers with elevated uric acid levels, and hope to build on this momentum with the goal of initiating a phase II clinical trial in patients with gout during the second half of 2025."
Dror Bashan, President and CEO
"We recorded revenues from selling goods of $53 million for the year ended December 31, 2024, an increase of 31% compared to 2023. The increase resulted primarily from an $11.8 million increase in sales to Chiesi. Our total research and development expenses decreased by 24% due to the completion of our Fabry clinical program and regulatory processes."
IL Rubin, Senior Vice President and CFO
Strategic Positioning
1. Strengthening Partnership with Chiesi
Protalix’s collaboration with Chiesi remains the cornerstone of its commercial success. The partnership’s focus on Elfabrio’s global commercialization and recent EMA approval for a less frequent dosing regimen enhances patient convenience and could expand the drug’s market penetration in Fabry disease. Chiesi’s ongoing investment in medical and commercial programs is expected to drive steady revenue growth and higher-margin royalty streams for Protalix through 2030 and beyond.
2. Advancing Pipeline with PRX-115
Protalix is progressing its recombinant PEGylated uricase candidate PRX-115, targeting uncontrolled gout. The successful Phase I trial demonstrated favorable safety and pharmacodynamics, with durable uric acid reduction. The company plans to initiate a Phase II clinical trial in the second half of 2025, budgeting approximately $20 million for third-party costs. Positive Phase II results could position PRX-115 for partnership discussions, reflecting a strategic approach to de-risk and commercialize this asset.
3. Focused R&D on Early-Stage Candidates
Beyond PRX-115, Protalix is developing PRX-119, a pegylated recombinant human DNase I for diseases related to neutrophil extracellular traps (NETs). While preclinical studies continue and indication selection is underway, management aims to update the market on potential indications and market size within one to two quarters. This pipeline diversification leverages Protalix’s ProCellEx platform and pegylation expertise to target rare renal diseases, aligning with the company’s long-term innovation strategy.
4. Financial Discipline and Balance Sheet Strength
The full repayment of the 7.5% senior secured convertible promissory notes in September 2024 and recent warrant exercises have materially improved Protalix’s balance sheet. With approximately $34.8 million in cash and short-term deposits at year-end, the company is well-positioned to fund ongoing R&D and commercial initiatives without immediate need for external financing, providing operational flexibility amid clinical development milestones.
5. Transition from Milestone-Driven to Commercial Revenue Model
The substantial decline in license and R&D service revenues reflects the completion of regulatory milestones for Elfabrio. Moving forward, Protalix anticipates minimal milestone payments, emphasizing the importance of growing product sales and royalties as the primary revenue drivers. This shift necessitates sustained commercial execution and partnership collaboration to maintain revenue momentum.
Key Considerations
Protalix's 2024 results highlight a critical transition phase balancing commercial growth with pipeline advancement.
- Revenue Concentration Risk: Heavy reliance on Chiesi for sales growth underscores the importance of this partnership’s stability and success.
- Pipeline Development Timing: The planned Phase II trial for PRX-115 is a key inflection point; enrollment pace and outcomes will materially impact future valuation.
- Clinical and Regulatory Execution: EMA’s acceptance of dosing variation for Elfabrio demonstrates regulatory progress but ongoing approvals will be vital for market expansion.
- Capital Allocation: Maintaining disciplined R&D spending while advancing multiple candidates reflects prudent resource management but may limit rapid pipeline expansion.
- Market Visibility: Limited disclosure of Chiesi’s sales data constrains near-term revenue visibility, requiring investors to rely on management’s qualitative commentary.
Risks
Protalix faces risks from its concentrated revenue base, particularly dependency on Chiesi’s commercial execution and regulatory approvals. Clinical development risks persist with early-stage candidates like PRX-115 and PRX-119, including enrollment challenges and uncertain efficacy outcomes. Additionally, geopolitical tensions in Israel and global market conditions could disrupt operations or supply chains. The absence of recurring milestone payments increases reliance on product sales, which may be impacted by competitive dynamics and reimbursement environments.
Forward Outlook
For the upcoming quarters, Protalix plans to initiate the Phase II trial for PRX-115 in the second half of 2025, with estimated third-party costs north of $20 million. The company expects to sustain and grow revenues from its three sales streams, particularly through Chiesi’s expanding Elfabrio commercialization efforts. Management did not provide explicit 2025 revenue guidance but emphasized a stable financial position to support R&D and commercial activities.
- Phase II trial commencement for PRX-115 targeted in H2 2025.
- Continued revenue growth anticipated from Chiesi partnership and other sales channels.
Management highlighted the strategic importance of their three revenue streams and a strong balance sheet as enablers for advancing pipeline development and commercial execution throughout 2025.
Takeaways
Protalix’s fiscal 2024 results reveal a company in transition from milestone-driven revenues to a commercial-stage biopharma with a growing product base and advancing pipeline.
- Commercial Execution Drives Growth: The 31% increase in selling goods revenues, mainly from Chiesi, underscores the critical role of strategic partnerships in Protalix’s business model.
- Pipeline Progress Sets Future Trajectory: Positive Phase I data for PRX-115 and planned Phase II initiation signal potential for significant value creation contingent on clinical success and subsequent partnerships.
- Financial Health Supports Strategy: Debt repayment and cash reserves provide flexibility to fund R&D and commercial initiatives, mitigating near-term financing risks.
Conclusion
Protalix BioTherapeutics demonstrated robust revenue growth in 2024 driven by its partnership with Chiesi and commercial sales of Elfabrio. The company’s disciplined expense management and strengthened balance sheet support its strategic focus on advancing promising pipeline candidates, particularly PRX-115. While near-term revenue visibility remains limited by milestone completion and partner confidentiality, the company is well-positioned for sustainable growth and innovation in rare disease therapeutics.
Industry Read-Through
Protalix’s transition from milestone-dependent revenues to a commercial sales model reflects a broader trend among biotech firms maturing their pipelines into marketed products. The emphasis on strategic partnerships, such as with Chiesi, highlights the importance of collaboration in rare disease markets where commercialization infrastructure and regulatory complexity are significant barriers. The advancement of plant cell-based expression platforms like ProCellEx signals growing industry interest in alternative biologic manufacturing technologies to reduce costs and improve scalability. Investors should monitor clinical progress and partnership dynamics in this sector, as these factors critically influence valuation and growth potential.